Reported 9 months ago
Senior reporter Li Jinqi, June 27, 2024, 6:34 AM Overseas fund performance for June is out, with 970 overseas funds (equities and bonds included) approved by the Financial Supervisory Commission and Securities and Futures Bureau showing an average increase of 1.05% as of the 26th. Among them, 695 equity funds registered an average increase of 1.14%, while 258 bond funds saw an average increase of 0.87%. In terms of sector funds, tech and biotech funds had the best performance in June, with average gains of 5.74% and 5.1% respectively. Indian and Taiwanese stock funds were the most robust, both with monthly average increases exceeding 6%. However, Latin American stock funds performed the worst, with an average decrease of 6.5% in June. Franklin Securities and Investment Advisory recommends a balanced U.S. fund as the core, and emphasizes tech and biotech industry-specific funds, Indian and Japanese stock funds, as well as green energy and infrastructure utility stock funds in the near term. New Kin Global Biotech & Medical Fund manager Jian Xiu Jun believes that with the ongoing release of biotech clinical trial results, small and medium-sized pharmaceutical stocks will continue to grow in July, with strategies focused on increasing the proportion of such stocks alongside opportunistic movements based on economic and market conditions.
Source: YAHOO